{"protocolSection":{"identificationModule":{"nctId":"NCT01042964","orgStudyIdInfo":{"id":"PR-15/01"},"secondaryIdInfos":[{"id":"EudraCT 2005-004656-12","type":"REGISTRY","domain":"EudraCT"}],"organization":{"fullName":"AdvanceCor GmbH","class":"INDUSTRY"},"briefTitle":"Safety, Pharmacokinetic and -Dynamic Study of PR-15, an Inhibitor of Platelet Adhesion","officialTitle":"An Open-Label, Dose-Escalating Safety and Pharmacokinetic Study of an Acute Intravenous Administration of PR-15, an Inhibitor of Platelet Adhesion, in Six Different Strengths in Healthy Male Volunteers","acronym":"PR-15/01"},"statusModule":{"statusVerifiedDate":"2012-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2006-03"},"primaryCompletionDateStruct":{"date":"2007-01","type":"ACTUAL"},"completionDateStruct":{"date":"2007-10","type":"ACTUAL"},"studyFirstSubmitDate":"2010-01-05","studyFirstSubmitQcDate":"2010-01-05","studyFirstPostDateStruct":{"date":"2010-01-06","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-10-18","lastUpdatePostDateStruct":{"date":"2012-10-19","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"AdvanceCor GmbH","class":"INDUSTRY"},"collaborators":[{"name":"Procorde GmbH","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"Primary objective:\n\nTo evaluate safety and tolerability, adverse events (AEs), vital signs, ECG, bleeding time, evaluation of antibody titer and safety laboratory tests\n\nSecondary objectives:\n\nTo evaluate the pharmacokinetics and pharmacodynamics (platelet aggregation)of six ascending single intravenous doses of PR-15 in healthy volunteers","detailedDescription":"Primary objective:\n\nTo evaluate safety and tolerability by using adverse events (AEs), vital signs including blood pressure/pulse rate (BP/PR), electrocardiographic examinations (12 lead ECG), bleeding time, evaluation of antibody titer and safety laboratory tests (biochemistry, hematology, coagulation, urinalysis)\n\nSecondary objectives:\n\nTo evaluate the pharmacokinetics and pharmacodynamics (collagen-induced platelet aggregation)of six ascending single intravenous doses of PR-15 in healthy, male volunteers"},"conditionsModule":{"conditions":["Thrombosis","Acute Coronary Syndrome","Myocardial Infarction","Stroke"],"keywords":["platelet adhesion and aggregation","acute coronary syndrome","myocardial infarction","stroke","inhibition of platelet adhesion to plaques","collagen-induced platelet aggregation"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":30,"type":"ACTUAL"}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"revacept (PR-15)","description":"single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.","otherNames":["GPVI-Fc dimer"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"safety and tolerability adverse events (AEs), vital signs (BP/PR), 12 lead ECG, bleeding time, antibody titer and safety laboratory tests","timeFrame":"43 days"}],"secondaryOutcomes":[{"measure":"pharmacokinetics and pharmacodynamics (agonist-induced platelet aggregation)","timeFrame":"43 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy, male Caucasians between 18 and 45 years of age.\n* Normotensive subjects (systolic BP \\< 140 mmHg and diastolic BP \\<90 mmHg;\n* Body weight of 70 to 90 kg (BMI 20 - 25.\n* Negative results in HIV antibody, HBs antigen (HBsAg) and HCV tests;\n* Signed Informed Consent Form.\n* Normal coagulation function (aPTT between 24 and 35 seconds, PT between 70 and 130%, INR between 0.85 and 1.15.\n\nExclusion Criteria:\n\n* Subjects who are taking or have taken any prescription medication within the last 14 days or any non-prescription medication, especially, anti-platelet drugs, within the last seven days prior to the administration of trial medication on Day 1.\n* Intake of any investigational drug within three months prior to the administration of study medication on Day 1.\n* Concomitant use of any other medication including over-the-counter preparations.\n* History of hypersensitivity, contraindication or serious adverse reaction to inhibitors of platelet aggregation or hypersensitivity to related drugs (cross-allergy) or to any of the excipients in the study drug.\n* A history or clinical evidence of any cardiac, cardio- or cerebrovascular, hepatic, renal, pulmonary, endocrine, neurological, infectious, gastrointestinal, haematological, oncological or psychiatric disease or emotional problems or any other clinically relevant condition, physical finding, ECG- or laboratory test abnormality, which - in the opinion of the investigator - would pose a significant risk for the subject, invalidate the Informed Consent or limit the ability of the subject to comply with study requirements or interfere otherwise with the conduct of the study.\n* Any laboratory value outside the normal laboratory reference range at Screening and before randomization, unless approved by the investigator.\n* Subjects known to have experienced elevated liver enzyme values will also be excluded.\n* History of alcohol and/or drug abuse (verified by drug screening).\n* Blood loss of 450 ml or more during the last three months before Screening.\n* Subjects who smoke more than 5 cigarettes per day and/or are unable to abstain from smoking during the entire in-house period.\n* Subjects who were previously enrolled in this trial or who have received PR-15 in a previous trial.\n* Subjects who have participated in other clinical trials in the last 3 months.","healthyVolunteers":true,"sex":"MALE","minimumAge":"18 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Richard Piechatzek, MD","affiliation":"ABX-CRO/Medifacts GmbH","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"ABX-CRO/Medifacts GmbH","city":"Goerlitz","state":"Saxony","zip":"02826","country":"Germany"}]},"referencesModule":{"references":[{"pmid":"21502572","type":"RESULT","citation":"Ungerer M, Rosport K, Bultmann A, Piechatzek R, Uhland K, Schlieper P, Gawaz M, Munch G. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation. 2011 May 3;123(17):1891-9. doi: 10.1161/CIRCULATIONAHA.110.980623. Epub 2011 Apr 18."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009203","term":"Myocardial Infarction"},{"id":"D000013927","term":"Thrombosis"},{"id":"D000054058","term":"Acute Coronary Syndrome"},{"id":"D000007238","term":"Infarction"},{"id":"D000000267","term":"Tissue Adhesions"}],"ancestors":[{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000007511","term":"Ischemia"},{"id":"D000009336","term":"Necrosis"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000016769","term":"Embolism and Thrombosis"},{"id":"D000002921","term":"Cicatrix"},{"id":"D000005355","term":"Fibrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","asFound":"Thrombosis","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M27235","name":"Acute Coronary Syndrome","asFound":"Acute Coronary Syndrome","relevance":"HIGH"},{"id":"M11845","name":"Myocardial Infarction","asFound":"Myocardial Infarction","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M3310","name":"Tissue Adhesions","asFound":"Adhesion","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"},{"id":"M7474","name":"Embolism","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"M5850","name":"Cicatrix","relevance":"LOW"},{"id":"M8175","name":"Fibrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}